Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 4/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.65 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 11/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL1957 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL3273179 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| SCHEMBL1437 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2166 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Hydrochloric Acid SCHEMBL2312 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL5042399 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1774275 | 0.95 | HTR1A (0.90) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2761861 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL6444414 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL221132 | 0.92 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | disclosed |
| US-12441709-B2 | Therapeutic compounds | INDIVIOR UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-20250230481-A1 | Compositions for CYP450 Phenotyping Using Saliva Samples | CONCORDIA UNIVERSITY, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | disclosed |
| WO-2025021790-A2 | MULTISPECIFIC ANTIBODIES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | disclosed |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20240033236-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-02-01 | — | — | US | disclosed |
| US-20230181847-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220277817-A1 | SOLID PHARMACEUTICAL AGENT DOSAGE FORM DISPENSING AND BIOMETRIC DATA ACQUISITION DEVICE | SUMNER BLUFFS LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220270733-A1 | SYSTEMS AND METHODS FOR DETERMINING COMPLIANCE AND EFFICACY OF A DOSING REGIMEN FOR A PHARMACEUTICAL AGENT | SUMNER BLUFFS LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220262507-A1 | PHARMACEUTICAL AND BIOLOGICAL AGENT DELIVERY SYSTEM HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220246263-A1 | NEBULIZING DEVICES AND SYSTEMS HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220160872-A1 | Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-05-26 | — | — | US | disclosed |
| EP-3989970-A1 | TRIPTAN MICROPORATION DELIVERY SYSTEM | PassPort Technologies, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022081773-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3962522-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H. Lundbeck A/S (DK) | 2022-03-09 | — | — | EP | disclosed |
| EP-3952841-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HTR1D 110/4885HTR1B 58/4885HTR1F 78/4885 |
| US-12441709-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | HTR1D 110/4885HTR1B 58/4885HTR1F 78/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HTR1D 217/4885HTR1B 91/4885HTR1F 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.